Sells Partial Stake in Immunocore
Munich, April 5, 2016 AEST (ABN Newswire) - Medigene AG (
MDG1:FRA) (MDGEF:OTCMKTS), a clinical stage immune-oncology company focussing on the development of T cell-based immunotherapies for the treatment of cancer, announces that it has today sold 50% of its' stake in the private biotech company Immunocore Ltd., UK, for approximately 4.9 million GBP (approx. EUR 6.1 million).
Medigene held 64,815 ordinary shares in Immunocore which were valued at 2.8 million GBP (approx. EUR 3.6 million) in 2014.
For more information, please visit http://www.medigene.com
About MediGene AG
Medigene AG (FRA:MDG1) is a biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative, complementary treatment platforms to target various types and stages of cancer with candidates in clinical and pre-clinical development. Medigene concentrates on the development of personalized T cell-based immunotherapies.
| ||
|
